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Background.  – Vestibular  schwannomas  (VS)  are  benign  tumors  of  the  vestibular  nerve’s  myelin  sheath.
The  current  trend  in VS surgery  is  to  preserve  at  the  facial  function,  even  if it means  leaving  a small
vestibular  schwannoma  tumor  remnant  (VSTR)  after  the  surgery.  There  is no  deﬁned  therapeutic  man-
agement  VSTR.  The  aim of  this  study  was  to  assess  the  evolution  of the VSTR  to  deﬁne  the  best  therapeutic
management  and  identify  predictive  factors  of VSTR  progression.
Methods. – Among  the  256  patients  treated  surgically  for  VS in the  Department  of  Neurosurgery  at  Angers
University  Hospital,  33  patients  with  a  post-surgical  VSTR  were  included  in this  retrospective  study.  For
all  surgical  patients,  the data  collected  were  age  at diagnosis,  the Koos  classiﬁcation,  the  surgical  access,
the  existence  of a type  2  neuroﬁbromatosis  (NF2),  the  TR  location  and  size  on control  MRI-scans.  Patients
had  a bi-annual  follow-up  with  clinical  status  and  VSTR  size  assessment  with  MRI-scan.  Survival  analyzes
were  performed  to determine  the  time  and  rate  of  VSTR  progression,  and identify  factors  of  progression.
Results. – The  mean  follow-up  of  the  population  was  51  months.  All  VS remnant  progression  occurred
between  38  and  58  months  after  surgery.  In non-NF2  patients  with  ﬁrst  follow-up  MRI-scan  three  months
after  surgery,  43%  presented  a spontaneous  regression,  50%  a  stability  and  7%  a  progression  of  the  VSTR.
In  the  same  population  with  the  1-year  MR-scan  after  surgery  as baseline,  25%  presented  a  sponta-
neous  regression,  62.5%  a stability  and  12.5%  a VSTR  progression.  These  data  are  consistent  with  the  data
reported  in the  literature.  The  post-operative  facial  function  impairment  and  an  initial  remnant  ≥  1.5  cm3
were  found  to be signiﬁcant  risk  factors  of  VS remnant  progression  in  non-NF2  population  in  univariate
analysis  (P  = 0.048  and  0.031)  but  not  in multivariate  analysis.
Conclusion. – In our  experience,  the  best  therapeutic  management  of the  post-surgical  VSTP  in  non-
NF2  patients  with  no  risk  factor  of  progression  is  a simple  clinical  radiological  follow-up  otherwise
complementary  radiosurgery  should  be considered.
©  2014  Elsevier  Masson  SAS.  
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Open access under CC BY-NC-ND license.ots clés : Introduction.  – Les  schwannomes  vestibulaires  (SV)  sont  des  tumeurs  bénignes  de la gaine  du  nerf vestibu-
chwannome vestibulaire laire.  La  tendance  actuelle  dans  la prise  en  charge  des  SV  est  de  conserver  la  fonction  faciale,  même  si
eurinome  de l’acoustique
eliquat  tumoral
adiochirurgie
cela  signiﬁe  laisser  un  reliquat  tumoral  (RT)  en  place  lors  de la  chirurgie.  Il n’existe  pas  de  prise  en charge
thérapeutique  déﬁnie  de  ce RT.  Le  but  de  cette  étude  est d’étudier  l’évolution  du RT  aﬁn  de  déterminer
la  meilleure  prise  en  charge  thérapeutique,  ainsi  que  les  facteurs  pronostiques  de  progression  du  RT.
Patients et  méthodes.  –  Nous  avons  réalisé  une  étude  rétrospective  portant  sur  256 patients  traités  chirur-
gicalement  pour  SV  dans  le département  de  neurochirurgie  du  CHU  d’Angers.  Trente-trois  patients
Abbreviations: GTR, gross total resection; IAC, internal auditory canal; NF2, type 2 neuroﬁbromatosis; Retrosig, retrosigmoidian surgical approach; Translab,
ranslabyrinthine approach; VS, vestibular schwannomas; VSTR, vestibular schwannomas tumor remnants.
 The  preliminary results of this study was  the subject of an oral communication at: Congress of the French Neurosurgical Society, Bordeaux, France, 22 Mars 2013; Congress
f  the French Speaking Association of Neuro-Oncologists, Bordeaux, France, 23 Mars 2013.
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E-mail address: lemee.jmichel@wanadoo.fr (J.-M. Lemée).
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028-3770/© 2014 Elsevier Masson SAS. Open access under CC BY-NC-ND license.
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porteurs  d’un  RT  conﬁrmé  sur  l’IRM  de  contrôle  ont  été inclus.  Pour  tous  les  patients  chirurgicaux,  les
données recueillies  étaient  l’âge  au moment  du  diagnostic,  la  classiﬁcation  de  Koos  de  la  lésion,  la  voie
d’abord chirurgicale,  l’existence  d’une  neuroﬁbromatose  de type  2 (NF2),  l’emplacement  du  RT  et  la
taille du  RT sur  les  scanners  de  contrôle.  Les  patients  ont  eu  un  suivi  bi-annuel  avec  bilan clinique  et
suivi de  la  taille  du RT  sur l’IRM  de  contrôle.  Des  analyses  de survie  ont  été  réalisées  aﬁn  de  déter-
miner le délai  et  le  taux  de  reprise  évolutive  du  RT, ainsi  que  les  facteurs  prédictifs  de cette  reprise
évolutive.
Résultats. –  La durée  de  suivi  moyen  de  la  population  était  de  51  mois.  Toutes  les  reprises  évolutives  de
RT de  schwannome  vestibulaire  sont  survenues  entre  38  et 58  mois  après  la  chirurgie.  Chez  les  patients
non NF2  avec  comme  IRM de  référence  celle  faite 3  mois  après  la  chirurgie,  43 % présentaient  une régres-
sion spontanée,  50 %  une  stabilité  et  7 % une  progression  du  RT. Dans  la  même  population  comme  IRM
de référence  celle  faite  1 an après  la  chirurgie,  25  % présentaient  une  régression  spontanée,  62,5  % une
stabilité et  12,5  %  une  progression  du  RT. Ces  résultats  sont  cohérents  avec  les  données  de  la littérature.
L’altération de  la fonction  faciale  post-opératoire  et un  volume  tumoral  initial  ≥  1,5 cm3 sont  signiﬁca-
tivement associés  à un  risque  de  progression  du  RT  de  VS  dans  la  population  non  NF2  en analyse  univariée
(p = 0,048  et  0,031)  mais  pas dans  l’analyse  multivariée.
Conclusion. –  La  prise  en  charge  thérapeutique  des  RT post-chirurgicaux  de  SV la plus  adaptée  chez
les patients  non-NF2  sans  facteur  de  risque  de  progression  semble  être un  suivi  clinico-radiologique
simple, tandis  qu’une  radiochirurgie  complémentaire  nous  semble  être  nécessaire  dans  les  autres
cas.
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t. Introduction
Vestibular schwannoma (VS) is an histologically benign tumor
rising from the schwannoma cell sheath of the vestibular portion
f the VIII cranial nerve. VS is the most common tumor of the
erebellopontine angle, with an incidence of 2/100 000 per year,
urrently increasing as the initial size at diagnosis has decreased.
hese changes in the epidemiology of the VS have been reported
s a consequence of the multiplication of brain MRI-scan investi-
ations [1,2]. Typically, VS clinical symptoms begin with otologic
ymptoms characterized by unilateral perception hearing loss. If
here is no subsequent treatment neurologic signs i.e. ataxia, gait
isturbance, facial function impairment or hydrocephalus may
hen appear.
There are three main possibilities in the management of VS:
 “wait-and-see” policy, consisting of a simple clinical follow-up
ith regular MRI-scan, primary radiosurgery or surgery. Decision
anagement of VS is complex and will depend on a multitude of
actors inﬂuencing the therapeutic approach.
VS localization in the cerebellopontine angle makes the surgery
 technical challenge. The previous trend in therapeutic manage-
ent was to treat VS surgically with a complete resection even at
he cost of an impairment of the facial function. However, currently
acial palsy is regarded as a severe handicap by the patient and is
o longer considered an acceptable post-operative result. This atti-
ude has led to a change of approach with the preservation of facial
unction as the ﬁrst aim of surgery, before the complete resection
f the VS [3–5].
Surgeons now prefer to leave a small remnant instead of risk-
ng the facial function of the patient by performing a complete
esection [6], and this change of attitude in VS surgery is leading to
n increase in the prevalence of post-operative vestibular schwan-
oma tumor remnants (VSTR), which makes the problematics of
STR management a more frequent question.
There is no deﬁned therapeutic approach towards this VS
emnant. Some surgical teams recommend routine radiosurgery
7–12] while other teams have adopted a “wait-and-see” attitude
13–15], keeping radiosurgery for regrowth of the VS remnant
16,17].Despite being safe compared to surgery, radiosurgery is not
ithout potential side effects and complications especially in a
ost-surgical cerebellopontine angle, and its place as a routine
reatment of a VS post-surgical remnant is widely discussed.©  2014  Elsevier  Masson  SAS. Tous  droits  réservés.
2. Aims of the study
The  objectives of this original study were to deﬁne the best ther-
apeutic attitude towards post-surgical VS remnant tumors and to
identify the factors of VS remnant progression.
3. Methods
3.1. Patient population
All  consecutive patients who underwent surgical treatment of
VS in the Department of Neurosurgery at Angers University Hos-
pital between 1977 and 1st May  2013 were included in the study.
They all underwent a planned gross total resection (GTR). The sur-
gical indication was  the appearance of neurological symptoms or
hydrocephalus. Most of the VS were stage III or IV in the Koos
classiﬁcation [18,19], and no longer had a useful hearing capac-
ity before surgery, with a Tokyo score of C or worse. The diagnosis
was conﬁrmed histologically in all cases.
3.2. Surgical technique
A  multidisciplinary team, made up of a neuro-otologist and
a neurosurgeon performed the surgical procedures. The pri-
mary surgical objective was the GTR and internal auditory canal
decompression, with preservation of the facial function. The
translabyrinthine approach, allowing a more effective exposition
of the internal auditory canal, was  favored, except in patients with
an ipsilateral partial hearing preservation, where the retrosigmoid
approach was  preferred in an attempt to preserve hearing. Facial
nerve function was  continuously checked during the intervention
by facial nerve monitoring. The surgical procedure was halted when
the facial nerve stopped responding to neurostimulation during
surgery or when the surgeon estimated that the beneﬁt/risk ratio
regarding facial function preservation was  weighed against the GTR
of the tumor, and chose to leave a small tumor remnant to avoid
any facial nerve lesions.
3.3.  Clinico-radiological follow-upAll patients beneﬁted from a multidisciplinary follow-up by
their neuro-otologist and neurosurgeon with regular consultations
and control MR-scans when available, or with CT-scan by default.
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evolution, the number of lesions, their evolution and the differ-
ent histology with hearing preservation as the main therapeutic
goal [22–24]. Therefore, to reﬁne our analysis and to differentiate
the potential therapeutic management approaches between NF2
Table 1
Characteristics of the population.
Caractéristiques  de la population.
Population, n = 33
Age at diagnosis (year) 52.4 ± 15.1
Initial volume before surgery (cm3) 9.8 ± 6.4
Koos stage
III  11 (33%)
IV  22 (67%)
Cystic  component 8 (24%)
NF2  3 (9.1%)
Surgical  access
Translabyrinthine 28 (85%)
Retrosigmoidian 5 (15%)
VSTR  location
CPA 19 (58%)
IAC  5 (15%)
Porus  9 (27%)
VSTR  size at ﬁrst checkup MRI-scan (cm3) 0.75 ± 2.36J.-M. Lemée et al. / Neuro
The ﬁrst consultation and clinico-radiological follow-up were
erformed three months after surgery. Therapeutic approach
owards the VS remnant was then decided depending on the size
f the residual tumor and the age of the patient.
Follow-up was at six months and then yearly after the ﬁrst post-
p consultation with clinical and MR-scan surveillance.
MRI-scans were carried out with a 1.5 T Siemens Magnetom
RI-scan. The chosen sequences were T1-weighted with and
ithout gadolinium enhancement, T2 High-resolution (CISS) and
2-FLAIR weighted, each with a slice thickness of 1 mm and a slice
pacing of 0.8 mm.  Assessment of the radiological follow-up was
erformed using the 3-plane radius of the tumor, data allowing
D reconstruction, which was unfortunately not available for all
atients.
.4. Data collection and analysis
We performed a retrospective study on patients treated or
ollowed up for a VS in the Department of Neurosurgery of the Uni-
ersity Hospital of Angers since its opening in 1977. The primary
nd-point for data collection and survival analysis was ﬁxed at the
st of May  2013.
All  the ﬁles of patients treated surgically with a planned GTR and
ith a per-operative tumor remnant described by the surgeon were
ollected and analyzed. Patients with a per-operative tumor rem-
ant and a “wait-and-see” therapeutic management of the VSTR
ere included for statistical analysis.
The following data were collected:
age at diagnosis;
the  initial VS size (in cm3);
Koos  stage;
existence of a cystic component;
existence  of a type 2 neuroﬁbromatosis (NF2);
surgical access;
per-operative tumor remnant size, estimated by the surgeon;
VSTR  location;
VSTR  size at each consultation during follow-up (in cm3);
follow-up  duration in months and the reason as well as the sec-
ondary  therapeutic decision that was made;
facial  nerve function before, after surgery and at the primary end-
point  using the House-Brackmann classiﬁcation [20].
The volume of the VS initial size and the VS remnant size was  cal-
ulated for each MR-scan using a contrast enhanced T1-weighted
equence or with injection-enhanced sequence in CT-scan. The
-plane tumor radii were measured on DICOM images using a mul-
iplanar reconstruction mode [21].
Statistical analysis was then carried-out with two-sample t-
ests, or Anova followed by a post-hoc test for the descriptive
nd comparative analysis of the different subpopulations. A Cox-
odel and Kaplan-Meier survival analysis were performed in the
earch for the remnant recurrence factors with remnant progres-
ion deﬁned as the primary event.
The regression of the VSTR was deﬁned by the reduction by
t least 25% of the VS volume between two successive MRI-scans
hereas progression was deﬁned by an increase of at least 10% in
olume.
Among patients with VS, we must distinguish those patients
ith NF2. Indeed, their different pathophysiological features make
hem stand out from the non-NF2 population by their clinical evo-
ution, the number of lesions, their evolution and the different
istology [22–24]. Therefore, to reﬁne our analysis and to differen-
iate the potential therapeutic management approaches between
F2 and non-NF2 patients, we decided to continue our analysis
ith non-NF2 patients alone. The evolution of the NF2 patients willrgie 60 (2014) 205–215 207
be discussed in a separate paragraph and due to the small number
of patients, their results will not be considered in the discussion.
4.  Results
4.1. Description of the population in the study
Among the 600 patients who were followed-up in our Depart-
ment of Neurosurgery for VS, 256 underwent surgery and 65
patients presented a per-operative VSTR described by the surgeon,
meaning a GTR rate of 74.6% (Fig. 1).
In this population of 65 patients, 17 patients with a VSTR
observed per-operatively by the surgeon did not have a radiolo-
gically conﬁrmed GTR. This produces a concordance rate of 74%
between the surgeon’s appreciation and the MRI-scan check with
an overestimation of the presence of a VSTR by the surgeon. In
addition, one patient died of meningitis before the ﬁrst checkup
MRI-scan and one patient discontinued the study due to a transfer
to another University hospital closer to his home for post-operative
surveillance and follow-up.
Among  the 46 remaining patients with a per-operative VSTR
conﬁrmed on the ﬁrst check-up MRI-scan, three sub-populations
with different therapeutic management approaches were deﬁned:
2 young patients had a planned 2-staged GTR and underwent a
second surgical intervention just after the ﬁrst checkup MRI-scan,
4 young patients with a large VSTR were referred immediately to
radiosurgery and 33 patients underwent a simple follow-up. We
also excluded 7 patients who  had recently undergone surgery and
had not undergone a MRI-scan check-up after the beginning of the
clinico-radiological follow-up to allow the radiological assessment
of VSTR evolution (Fig. 1, Table 1).
Therefore, in our study we included the 33 patients who had a
per-operative VSTR conﬁrmed on the ﬁrst MRI-scan and who had
undergone a basic follow-up.
4.2.  Evolution of the “wait-and-see” population
Among patients with VS, patients with NF2 must be distin-
guished. In fact, their different pathophysiological features make
them stand out from the non-NF2 population due to their clinicalFollow-up duration (months) 60  ± 65.3
Mean pre-operative facial function 1 ± 0.2
Mean post-operative facial function 2.53 ± 2
Mean facial function at end-point date 2 ± 1.66
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Diagramme de ﬂux de la population de patients su
nd non-NF2 patients, we  decided to continue our analysis with
on-NF2 patients alone. The evolution of the NF2 patients will be
iscussed in a separate paragraph.
.2.1. “Wait-and-see” non-NF2 patients with reference MRI-scan
 months after surgery
Thirty  non–NF2 patients had a radiological remnant on the MRI-
can 3 months after surgery and a follow-up of more than a year.
n this population of 30 non-NF2 patients, with reference MRI-scan
t 3 months after surgery, we observed a progression of the VSTR
n 7% of the population, 50% with tumor remnant stability and 43%
ith spontaneous regression (Fig. 2).
The average follow-up duration was 45 months for the patients
ith a spontaneous VSTR regression, 57 months for the stable group
nd 48 months for the progression group (Table 2). No statistical
ifference was observed between the different durations of follow-
p (p = 0.84).
Univariate analysis showed a signiﬁcant association between
n impaired facial function after surgery and the progression of
he post-surgical VSTR in non-NF2 patients (p= 0.02 in univariate
Fig. 2. Description of the population of VS non NF2 patients with a per-operative VSTR
Description  de la population de patients non NF2 opérés d’un schwannome vestibulaire ave followed-up at Angers University Hospital.
ur un schwannome vestibulaire au CHU d’Angers.
analysis).  We  also observed a strong association between large VS
before surgery and a large VSTR with the risk of recurrence (both
p= 0.06) (Table 2).
In  multivariate analysis, the VS remnant size was signiﬁcantly
higher in the progression group versus the stable group (p = 0.039).
4.2.2. “Wait-and-see” non-NF2 patients with a reference
MR-scan one year after surgery
The delay between surgery and the ﬁrst post-operative MRI-
scan, usually done 3 to 12 months post-operatively, remains subject
to debate. The main risk of an early post-operative MRI-scan is
the confusion between a post-operative tumor remnant and post-
operative scar tissue, which may lead to a false over estimation
of the post-surgical remnant rate. To minimize this risk, we ana-
lyzed the same population of patients and the evolution of VS
post-surgical remnant using the 1-year post-op MRI-scan as a ref-
erence.
Sixteen non–NF2 patients had a radiological remnant on the
MR-scan 1 year after surgery and a follow-up of more than a year
after the MRI-scan reference. The number of patients was lower
 described by the surgeon. First check-up MRI-scan three months after surgery.
c un reliquat décrit en per-opératoire par le chirurgien. 1re IRM de contrôle à 3 mois.
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Table  2
Univariate analysis and description of the evolution of VSTR in the non-NF2 “wait-and-see” population.
Analyse  univariée et description de l’évolution de VSTR dans la population non-NF2 wait-and-see.
Regression
n = 13
Stability
n = 15
Progression
n = 2
P value
Age at diagnosis (year) 55.3 ± 12.3 48.9 ± 17.9 62 ± 22.6 0.64
Initial  volume before surgery (cm3) 7.4 ± 7.2 11 ± 6 14 ± 1.8 0.06
Koos stage 0.67
III  5 (38%) 6 (40%) –
IV  8 (62%) 9 (60%) 2 (100%)
Cystic  component 3 (23%) 3 (20%) 1 (50%) 0.67
Surgical  approach 0.59
Translabyrinthine 12 (92%) 13 (87%) 2 (100%)
Retrosigmoidian 1 (8%) 2 (13%) –
VSTR  location 0.17
CPA  5 (38%) 11 (73%) 1 (50%)
IAC  4 (31%) 1 (7%) –
Porus  4 (31%) 3 (20%) 1 (50%)
VSTR  size at ﬁrst checkup MRI-scan 1.1 ± 3.1 0.1 ± 0.2 14 ± 1.8 0.06
Mean  follow-up duration (months) 44.6 ± 26.7 56.6 ± 67.8 48 ± 14.1 0.84
Mean  pre-operative facial function 1 ± 0 1.1 ± 0.3 1 ± 0 0.16
Mean  post-operative facial function 2.7 ± 2.2 1.9 ± 1.6 5.5 ± 0.7 0.02
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aMean facial function at end-point date 1.9 ± 1.9 
han the previous group with ﬁrst MRI-scan 3 months after surgery.
ine patients had an insufﬁcient follow-up duration and thus were
xcluded, and 5 patients were excluded and considered as GTR
ecause of the absence of a remnant on the 1-year MR-scan.
In  this population, we observed a progression of VSTR in 12.5%
f the population, 62.5% with stability and 25% with spontaneous
egression (Fig. 3). The average follow-up duration was 43 months
or the patients with a spontaneous VSTR regression, 65 months
or the stable group and 37 months for the progression group
Table 3).
Also  in this group, there was a signiﬁcant association between
ost-surgical facial function and the VSTR evolution in univariate
nalysis (p= 0,01), conﬁrmed in the multivariate analysis (p= 0.05)
Table 3).
.2.3.  NF2 patients
In  the literature, NF2 patients are considered a speciﬁc entity
mong VS patients, with a speciﬁc medical history and speciﬁc
anagement. In our study, 3 NF2 patients were included, rep-
esenting 9.1% of the population with a post-operative tumor
emnant shown on the MRI-scan at 3 months.
Among the NF2 population, 2 out of 3 patients presented a VS
emnant progression, corresponding to a 66% progression rate, with
ne late progression observed 25 years after the ﬁrst surgery. With
hese 2 VSTR progressions, NF2 patients represent half of the VSTR
rogression in the entire population of patients, despite the low
revalence of NF2 in the population.
Due to the small number of NF2 patients included, no statistical
ifference was shown between the NF2 and non-NF2 population
nd no risk factor of VSTR progression was identiﬁed. Due to the
Fig. 3. Description of the population of VS non-NF2 patients with a per-operative VS
Description de la population de patients non NF2 opérés d’un schwannome vestibulaire av1.7 ± 1.3 4 ± 2.8 0.47
small  number of NF2 patients, they were not included in the dis-
cussion.
5. Survival analysis of VS remnant growth
5.1. Non-NF2 population
5.1.1.  Overall survival curve
In  the entire non-NF2 population (n = 30), the average follow-up
duration was 51 months and the median of 37 months. All VS rem-
nant progression occurred between 38 and 58 months after surgery
(Fig. 4).
5.1.2. Statistical analysis
Univariate  analysis showed a signiﬁcant risk of progression in
patients with an initial tumor remnant volume ≥ 1.5 cm3 or a post-
operative facial nerve function score ≥ 4 on the House-Brackmann
scale (P = 0.048 and 0.031) (Fig. 5A and B). Neither the initial tumor
volume, nor the existence of a cystic component, the Koos stage,
the surgical approach, the initial VSTR size or location, or the pre-
operative facial function were found to be a prognostic factor of
VSTR progression.
Multivariate analysis did not show any signiﬁcant difference
because of the small number of patients in the population.However, despite a lack of signiﬁcance, we observed that all
remnant progression occurred in Koos IV patients (P = 0.6) and no
recurrences of remnants located in the internal auditory canal were
observed (P = 0.82).
TR described by the surgeon. First check-up MRI-scan one year after surgery.
ec un reliquat décrit en per-opératoire par le chirurgien. 1re IRM de contrôle à 1 an.
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Table 3
Univariate analysis and description evolution of VS TR in the non-NF2 “wait-and-see” population with ﬁrst MRI-scan at one year after surgery.
Analyse  univariée et description de l’évolution du reliquat post-chirurgical de schwannome vestibulaire dans la population non NF2 sous simple surveillance. IRM de référence 1 an
après  chirurgie.
Regression
n = 4
Stability
n = 10
Progression
n = 2
P value
Age at diagnosis (year) 59.8  ± 3 47.3 ± 13.8 62 ± 22.6 0.61
Initial  volume before surgery (cm3) 9.6 ± 12.9 10.4 ± 5.5 14 ± 1.8 0.14
Koos  stage 0.21
III  2 (50%) 5 (50%) -
IV  2 (50%) 5 (50%) 2 (100%)
Cystic  component 2 (50%) 1 (10%) 1 (50%) 0.67
Surgical  access 0.64
Translabyrinthine 4 (100%) 8 (80%) 2 (100%)
Retrosigmoidian – 2 (20%) –
VSTR  location 0.5
CPA  1 (25%) 8 (80%) 1 (50%)
IAC  2 (50%) – –
Porus  1 (25%) 2 (20%) 1 (50%)
VSTR  size at ﬁrst checkup MR-scan 3.1 ± 5.6 0.1 ± 0.2 4 ± 5.6 0.59
Mean  follow-up duration (months) 38 ± 20 65.6 ± 75.3 31 ± 7.1 0.16
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nMean  pre-operative facial function 1 ± 0
Mean post-operative facial function 3 ± 2.5 
Mean  facial function at end-point date 2.5 ± 2.3 
.1.3. Comparison with non-NF2 population, ﬁrst MR-scan one
ear  post-op
In  this population (n = 16), the two signiﬁcant VSTR main
rogressions occurred at 26 and 46 months after surgery
Fig. 6A).
Univariate analysis showed, as in the non-NF2 group, a signiﬁ-
antly increased risk of tumor remnant progression in patients with
 postoperative function score ≥ 4 (P = 0.021) (Fig. 6B).
However, in this group, the presence before surgery of VIIth
erve impairment with a score ≥ 2 is associated with a signif-
cant risk of progression (P = 0.001) (Fig. 6C). The initial VSTR
ize was not considered a progression factor in this group
P = 0.193).
ig. 4. Non-progression survival curve for non-NF2 patients with VS remnant. x-
xis: time in months after surgery, y-axis: probability of non-progression.
ourbe  de non-progression du reliquat tumoral chez les patients non NF2 porteur s’un
eliquat tumoral post-chirurgical. Abscisse : temps en mois, ordonnée : probabilité de
on progression du reliquat tumoral.1.2 ± 0.4 1 ± 0 0.16
1.8 ± 1.4 5.5 ± 0.7 0.01
1.8 ± 1.4 4 ± 2.8 0.5
5.2. NF2 population
Two  NF2 patients presented a VSTR, one at 48 months and one
at 300 months (25 years) after surgery (Fig. 7).
Due to the small number of NF2 patients included, survival
analysis was not performed on this population because of the pre-
dictable lack of signiﬁcance.
However,  in the survival analysis of the entire population, the
existence of an NF2 was not found to be a signiﬁcant risk factor of
progression (P = 0.5).
6.  Discussion
The therapeutic management of post-surgical VS remnants is a
crucial debate in an era where the preservation of the facial function
at all costs leads to an increase in their prevalence.
The management of post-surgical VS requires physicians to
identify predictive factors of progression and to characterize the
different sub-populations. The aim is to choose the best therapeu-
tic approach for each patient with the most appropriate beneﬁt/risk
ratio, its particularities and its individuality among the VS patient
population.
Our study is, to our knowledge, the ﬁrst to focus on the natural
history of VS post-surgical remnants and to establish the predic-
tive factors of progression. This original study might shed new light
on the optimal therapeutic attitude towards post-surgical VS rem-
nants. We  suggest following-up the results with a post-surgical VS
remnant assessment that may  help to select patients who are at a
high risk of progression.
The  main limitation of this study is its retrospective analysis,
posing the problem of non-homogenous follow-up, missing data
and patients lost to follow-up during the study. VS prevalence is
low among the general population, making a prospective study long
and difﬁcult to undertake to reach the statistical level required to
demonstrate the existence of predictive factors in VSTR progression
between multiple variables.
This study also presents a selection bias, with 2-stage surgery
chosen by the surgeons for younger people and routine radio-
surgery for young people with major post-surgical VSTR. These
strategies were chosen by the surgeons to minimize the recur-
rence rate, data regarding the VSTR progression rate and natural
evolution under surveillance not currently available.
However, this study does not present an attrition bias, nor an
evaluation bias. All patients, even those patients lost to follow-up in
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Fig. 5. Kaplan-Meier stratiﬁcation of VSTR non-progression survival curves and ﬁrst MR-scan three months after surgery. x-axis: time in months after surgery, y-axis:
probability of non-progression, notches and circles: censored data. A. Stratiﬁcation by VS remnant volume with cut-off ≥ 1.5 cm3. B. Stratiﬁcation by postoperative facial
function with cut-off ≥ 4.
Stratiﬁcation selon la méthode de Kaplan-Meier des courbes de non-progression du reliquat post-chirurgical de schwannome vestibulaire. IRM de référence 3 mois après la chirurgie.
Abscisse  : temps en mois, ordonnée : probabilité de non progression du reliquat tumoral. A. Stratiﬁcation en fonction du volume du reliquat post-chirurgical de schwannome vestibulaire
avec  un cut-off ≥ 1,5 cm3. B. Stratiﬁcation en fonction de la fonction faciale en post-opératoire immédiat avec cut-off ≥ 4.
Fig. 6. Survival curves for non-NF2 patients with VSTR and ﬁrst MRI-scan one year post-operatively. x-axis: time in months after surgery, y-axis: probability of non-progression.
A. Overall survival curve. B. Stratiﬁcation by post-operative function with cut-off ≥ 4. C. Stratiﬁcation by pre-operative facial function with cut-off ≥ 2.
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aourbes  de survie de non-progression du reliquat tumoral chez les patients non-NF2 por
emps  en mois, ordonnée : probabilité de non-progression du reliquat tumoral. A. Cou
mmédiat avec cut-off ≥ 4. C. Stratiﬁcation en fonction de la fonction faciale en pré-opé
he study, were included and the same surgeon performed a routine
valuation at regular time intervals.
. Timing of the radiological assessment after VS surgeryThe  most appropriate timing for an MRI-scan assessment of the
xistence of VSTR after surgery is subject to debate between early
nd delayed post-surgical checkups.un reliquat tumoral post-chirurgical. IRM de référence 1 an après la chirurgie. Abscisse :
 survie globale. B. Stratiﬁcation en fonction de la fonction faciale en post-opératoire
e immédiat avec cut-off ≥ 2.
The  risk of an early MRI-scan check-up is to confuse VSTR with
post-surgical scaring because of the similar gadolinium enhance-
ment pattern. This distinction is critical for our study because of
the spontaneous regression of the post-surgical scar, which can be
confused with the spontaneous regression of a VSTR.
In  our study, all VSTR patients had the presence of the VSTR
conﬁrmed both per-operatively by the surgeon and radiologically
on the control MRI-scan. This double conﬁrmation minimizes the
212 J.-M. Lemée et al. / Neurochiru
Fig. 7. Survival curves for VSTR non-progression in the whole population, stratiﬁed
by  the presence of an NF2. x-axis: time in months after surgery, y-axis: probability
of  non-progression, notches and circles: censored data.
Stratiﬁcation de la probabilité de non-progression du reliquat post-chirurgical de
schwannome vestibulaire en fonction de la présence ou non d’une NF2. Abscisse : temps
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remnant volume are found to be signiﬁcant predictive factors ofn mois, ordonnée : probabilité de non progression du reliquat tumoral.
isk of confusion between a VSTR and a post-surgical scar in our
tudy.
Despite its interest in reducing the risk of confusion between
ost-surgical scaring and VSTR, the disadvantage of the use of a 1-
ear post-op MRI-scan after surgery is a loss of information about
arly VSTR evolution. In our study, ﬁve patients with VSTR pre-
ented a complete spontaneous regression of their tumor remnant
uring the ﬁrst year. This data could have been ignored and would
ave led to a false increase of the GTR of VS and a lowering of the
STR spontaneous regression rate, if only the data based on the
-year post surgical MR-scan had been considered.
In our experience, the 3-month post-op MRI-scan should be
iven priority for VSTR conﬁrmation and the follow-up should be
iven priority for the per-operative and radiological conﬁrmation
f the existence of a VSTR making the risk of a false positive unlikely.
. Comparison of VS remnant evolution and progression
ate with the literature
In  non-NF2 patients with the ﬁrst MRI-scan three months post-
p, the progression rate was 7%. This result is inferior to the
0% recurrence rate found in a recent study, which excluded NF2
atients and treated all post-surgical VS remnants via radiosurgery
8].
Considering this patient population, its seems more appropriate
o adopt a “wait-and-see” attitude instead of a routine radiosurgical
reatment of VS surgical remnant, the beneﬁt/risk balance being
learly in favor of a simple follow-up.
With one year post-op MRI-scan as reference, only 16 patients
ad sufﬁcient follow-up to be included, making this population less
epresentative and the statistical signiﬁcance poorer.In  this case, we found a progression rate of 12%, equivalent
o the overall population characteristics and slightly higher than
he previous rates found in the literature [8,25]. The populationrgie 60 (2014) 205–215
reduction explained in the results may  be, in our estimation, the
primary explanation for the increase of the progression percentage.
In our experience, the therapeutic management of post-surgical
VS in non-NF2 patients should be a “wait-and-see” policy, the pro-
gression rate being equivalent or lower than in patients treated
systematically with radiosurgery.
9.  Predictive factors of VS remnant growth
This original study is the ﬁrst, to our knowledge, to assess
the natural history of VS post-surgical remnants, to deﬁne the
best therapeutic attitude and the factors of VSTR progression with
the characterization of sub-populations at a high risk of recur-
rence. After demonstrating that the “wait-and-see” policy should
be given priority for non-NF2 patients, we  decided to continue
our investigation and attempt to establish predictive factors for
recurrence.
In the entire population, we observed that almost all VS
remnant progression occurred three to ﬁve years after surgery.
The data of our retrospective study is in agreement with the
literature [15,26]. However, with a median follow-up of 37
months, we  cannot fully predict the long term risk of VS rem-
nant progression. Thus, this explains why  numerous cases of
very late progression of VS remnants have been reported in the
literature.
In each population the immediate post-operative facial func-
tion impairment ≥ 4 based on the House-Brackmann grading scale
was statistically associated with a progression of the remnant.
When examining the patient’s ﬁle, this was explained by an altered
per-operative facial function, leading the surgeon to end the inter-
vention prematurely to preserve the facial function. This means
leaving an unplanned VS remnant in size and location, with unsa-
tisfactory surgery in the surgeon’s opinion. The unplanned size of
the VS remnant may  be an explanation of the statistical association
between post-operative facial function alteration and VS remnant
progression, as the size of the remnant is a known factor of sec-
ondary progression.
In  non-NF2 patients, the initial VS remnant volume also appears
to be a statistically signiﬁcant progression predictor, with a cut-off
point at 1.5 cm3, inferior to the 2.5 cm3 cut-off point previously
described by Vakilian et al. [27]. This predictive factor may be
explained by the less efﬁcient devascularization of large tumor
remnants.
All recurring VS remnants were primary grade IV on the Koos
classiﬁcation, suggesting a potential statistical association between
the initial size of the VS and the risk of recurrence. However, the
Koos stage and therefore the initial volume of the VS was  not found
to be a statistically signiﬁcant predictive factor, as described in
previous studies [5,28,29].
Also,  no signiﬁcant progression was  found with VS remnants
located in the internal auditory canal (IAC), consistent with the lit-
erature, where no progression of VS located in the IAC was observed
[15,30].
Due to lack of statistical signiﬁcance, the initial VS remnant vol-
ume was  not found to be a predictive factor of progression in the
population with the ﬁrst MR-scan at one year after surgery. Instead,
we found a signiﬁcantly increasing risk of recurrence with the alter-
ation of pre-operative facial function even with a small impairment
(House-Brackmann score ≥ 2), which can be interpreted more as a
statistical association than a cause-effect link in this patient popu-
lation.
Post-operative facial function impairment and the initial VSprogression in the non-NF2 population.
We also observed that all growing VS remnants were initially
Koos grade IV and no VS remnant progression was observed on VS
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ere not statistically signiﬁcant.
0. Post surgical VS remnants: therapeutic management
roposal
Three therapeutic options are available for the management of
ost-surgical VS remnants: a “wait-and-see” attitude, radiosurgery
nd surgery.
A  “wait-and-see” attitude is based on a regular clinical-
adiological follow-up. The goal is to avoid routine radiosurgical
reatment of VS remnants. Only the few remnants that will progress
ver time in the population presenting a low progression rate will
e retained. The inconvenient of this therapeutic management is
he delay in treating the progression and the increased difﬁculty
f treating an important remnant tumor instead of a small post-
perative remnant.
Radiosurgery is considered an effective technique providing a
inimally invasive treatment at low risk for primary VS man-
gement [10,31–36]. However, for post-surgical VS remnants, its
ndications remain unclear. Nevertheless, even if it is a minimally
nvasive treatment, radiosurgery may  have side-effects and com-
lications. Ito et al. described 36% of transient facial palsy and
.6% of severe permanent facial palsy and 14% of total hearing
oss in patients with partially preserved hearing [28,37]. In clinical
ractice, radiosurgery in treatment of VS remnants is acceptable
nly if its beneﬁts surpass its potential risks compared to other
herapeutic options.
Re-operation is considered less often, due to its technicality,
ith an major risk of complications higher than the two previous
herapeutic options with cranial nerve impairment and cerebro-
pinal ﬂuid leakage. Ramina et al. reported in their study of VS
e-operation that 7% of cases had facial nerve lesions, 13% had tran-
ient bulbar nerve palsy and 20% had cerebro-spinal ﬂuid leakage
n a group of 15 patients [38]. One option to be considered in this
ategory is the 2-staged surgery for large VS, that can improve facial
utcome and diminish the morbidity [39].We suggest therapeutic management for patients with radio-
ogically conﬁrmed VS remnants depending on the criteria
ighlighted in this study (Fig. 8).
ig. 8. Therapeutic management proposal for VS post-surgical remnant in non-NF2
atients.
roposition de prise en charge thérapeutique des patients non NF2 porteurs d’un reliquat
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MRI-scans remain the radiological exam of choice to monitor the
evolution of post-surgical tumor remnants, with T1 with and with-
out gadolinium enhancement, T2 high-resolution and T2-FLAIR
weighted, each in 3D acquisitions. The poor correlation between
the surgeon and the MRI-scan checks to determine the existence
of a post-operative remnant makes the ﬁrst check-up MRI-scan
the best check with a sensitivity and a speciﬁcity up to 100%
[40].
The ﬁrst MRI-scan one year after surgery may permit us to
minimize the risk of confusing a post-surgical scar for a VS
remnant despite losing information about the early regression
of post-surgical VS remnants. However, we  chose to perform
the ﬁrst MRI-scan three months after surgery to allow early
detection of post-surgical complications, and monitor early VS
remnant regression, as in the series reported by Roche et al.
[12].
In the non-NF2 population, patients with an impaired facial
function, a score ≥ 4 on the House and Brackmann grading scale
and patients with a VS remnant size ≥ 1.5 cm3 had a statistically
increased risk of progression. Therefore, we  suggest complemen-
tary radiosurgical treatment for these sub-populations of non-NF2
patients at risk of progression.
For  patients with a VS remnant, all progression occurred
between three and ﬁve years after the ﬁrst surgery. This suggests
that a close follow-up during the ﬁrst six years after surgery is
needed, and can be more widely spaced after this critical period
of surveillance (Fig. 8).
In  our therapeutic management proposal, we suggest treating
non-NF2 patients with an impaired post-operative facial func-
tion with radiosurgery. This choice of treating patients with an
already impaired facial function with radiosurgery may  be ques-
tionable due to the risk of aggravation. Nevertheless, in our study,
because of a statistically signiﬁcant risk of VS remnant growth in
this population, we considered the beneﬁt/risk ratio in favor of the
radiosurgery treatment.
11.  Spontaneous remnant regression: myth or reality?
The  existence of spontaneous regression of post-surgical VS
remnants is subject to question. Only a few studies have reported
its existence and radiological behavior [14,41]. It is often attributed
to a post-surgical scar.
In  our study, spontaneous regression of post-operative rem-
nants occurred in 39% of the overall population and 43% in the
non-NF2 population with a ﬁrst MR-scan three months after
surgery.
The regression of the post-operative remnant seems to occur
shortly after surgery. In our study, spontaneous regression of VS
remnants happened in the ﬁrst year after surgery in 60% of cases.
This means that an important part of this population is excluded in
the one-year post-operative analysis and in studies based on 1-year
post-surgery MRI-scans.
Distinction  between a VS remnant and a post-surgical scar can
be confusing, requiring authors to be cautious about the interpreta-
tion of the rapid disappearance of contrast-enhanced lesion located
in the surgical site. However, we  think that we can safely afﬁrm that
no confusion was made between VS remnant and post-surgical scar
in this study, since each VS remnant was described per-operatively
by the surgeon and the tumor remnant location on ﬁrst check-up
MRI-scan exactly matched the remnant described by the surgeon,
as shown in Fig. 9.
The  mechanisms of the VS remnant regression remain unclear.
One main explanation may  be the devascularization of the
remnant tumor during surgery, as described by Hahn et al.
[14].
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Fig. 9. Vestibular schwannoma remnant spontaneous regression. Illustrative case of a 50-year-old patient. A. Vestibular schwannoma remnant on control MR-scan one year
after  surgery. B and C. Complete regression of the vestibular schwannoma remnant on MR-scan two  years after surgery.
Régression spontanée d’un reliquat tumoral de schwannome vestibulaire. Cas illustratif d’une patiente de 50 ans. A. reliquat tumoral visible sur l’IRM post-opératoire à 1 an. B et C.
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2. Conclusion
Initial VS remnant size ≥ 1.5 cm3 and immediate post-operative
acial function impairment with House-Brackmann score ≥ 4 are
tatistically associated with a signiﬁcant risk of VS remnant pro-
ression in non-NF2 patients.
In  our opinion, the best therapeutic management of VS post-
urgical remnants in non-NF2 patients with no predictive factor
f progression is a simple clinical-radiological follow-up whereas,
atients with a least one of the predictive factors of progression
ay in fact beneﬁt from radiosurgery.
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